Skip to content

Homeopathy in Postmenopausal Osteoporosis

Homoeopathic Medicine In Cases of Postmenopausal Osteoporosis: A, Randomized, Double-Blind, Placebo Controlled Pilot Trial - NIL

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/04/086027
Enrollment
40
Registered
2025-04-30
Start date
Unknown
Completion date
Unknown
Last updated
2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M80- Osteoporosis with current pathological fracture Health Condition 2: M81- Osteoporosis without current pathological fracture

Interventions

Intervention1: Homoeopathic medicine: Each dose consists of 6 -8 cane sugar globules no.30 moistened with the medicine preserved in 90%v/v ethanol to be taken orally on a clean tongue with an empty st

Sponsors

DG,Central Council for Research in Homoeopathy (CCRH), Ministry of AYUSH, Govt. of India.
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Participant having postmenopausal osteoporosis (diagnosed clinically and /or by Bone Densitometry/ DXA scan) and T-score -2.5 or below as per criteria. (WHO criteria) 2. Participant of diagnosed PMO with current pathological fracture and asymptomatic. 3. Postmenopausal women aged 45 to 65years of age. 4. Postmenopausal for at least 1 year (Menopause as having permanent cessation of menses for at least 12 months (as per current guidelines) without any other obvious pathological or physiological cause. 5. Participants who are not under any therapy or medications for PMO 6. Participant willing to give consent for the study

Exclusion criteria

Exclusion criteria: 1. Participant who are suffering secondary osteoporosis and serious illness /or suffering from critical illness 2. Participants who are pregnant or/ and lactating mothers and those who have glucocorticoid-induced osteoporosis 3. Deranged renal function, any significant liver disease 4. Participant who has received estrogen replacement therapy (within the previous 12 months. 5. Participant who are severely drug/alcohol addicted. 6. Participants having mental and behavioral disorders due to psychoactive substance other than tobacco

Design outcomes

Primary

MeasureTime frame
T-SCORE with help of DEXA scan Changes in Bone mass densityTimepoint: Baseline, 12 months and 30 Months.

Secondary

MeasureTime frame
Serum Calcium, Serum 25-hydroxyvitamin DTimepoint: Baseline, 12months and 30 Months (End Of Treatment );QUALEFFO-41,Quality of Life for Osteoporosis, Osteoporosis Assessment Questionnaire-Physical FunctionTimepoint: Baseline/16Week/6 Months/9Months/12 Months till end treatment.

Countries

India

Contacts

Public ContactDr Gurudev ChoubeyPhDMDHom

DACRRI(H).Kolkata

gurudev.choubey@gmail.com9475916907

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Sep 19, 2026